144 related articles for article (PubMed ID: 26493102)
1. Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect.
Mintzes B; Lexchin J; Quintano AS
Br Med Bull; 2015; 116():43-53. PubMed ID: 26493102
[TBL] [Abstract][Full Text] [Related]
2. Access to regulatory data from the European Medicines Agency: the times they are a-changing.
Wieseler B; McGauran N; Kerekes MF; Kaiser T
Syst Rev; 2012 Oct; 1():50. PubMed ID: 23110993
[TBL] [Abstract][Full Text] [Related]
3. Fostering EMA's transparency policy.
Banzi R; Bertele' V; Demotes-Mainard J; Garattini S; Gluud C; Kubiak C; Ohmann C
Eur J Intern Med; 2014 Oct; 25(8):681-4. PubMed ID: 25200801
[TBL] [Abstract][Full Text] [Related]
4. European Federation of Statisticians in the Pharmaceutical Industry's position on access to clinical trial data.
Fletcher C; Driessen S; Burger HU; Gerlinger C; Biesheuvel E;
Pharm Stat; 2013; 12(6):333-6. PubMed ID: 24136872
[TBL] [Abstract][Full Text] [Related]
5. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
6. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
7. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
8. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
9. More transparency for clinical trial data: The decision by the European Medicines Agency to make clinical trial reports publicly available could provide a boon for biomedical research.
Hunter P
EMBO Rep; 2015 Jan; 16(1):21-3. PubMed ID: 25476710
[No Abstract] [Full Text] [Related]
10. Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry.
So D; Joly Y; Knoppers BM
Public Health Genomics; 2013; 16(6):322-35. PubMed ID: 24503593
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
Rawal B; Deane BR
Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
[TBL] [Abstract][Full Text] [Related]
12. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013.
Deane BR; Sivarajah J
Curr Med Res Opin; 2017 Mar; 33(3):473-478. PubMed ID: 27869482
[TBL] [Abstract][Full Text] [Related]
14. Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability.
Hopkins AM; Rowland A; Sorich MJ
BMC Med; 2018 Sep; 16(1):165. PubMed ID: 30261889
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
16. European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research.
Ferran JM; Nevitt SJ
BMC Med Res Methodol; 2019 Nov; 19(1):204. PubMed ID: 31690260
[TBL] [Abstract][Full Text] [Related]
17. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
Lipworth W; Doran E; Kerridge I; Day R
Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
[TBL] [Abstract][Full Text] [Related]
18. Europe. Drug watchdog ponders how to open clinical trial data vault.
Rabesandratana T
Science; 2013 Mar; 339(6126):1369-70. PubMed ID: 23520086
[No Abstract] [Full Text] [Related]
19. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
Rawal B; Deane BR
Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
[TBL] [Abstract][Full Text] [Related]
20. Regulatory transparency: social, technical, and ethical aspects of clinical trial data access.
Sousa VD; Silveira D
Rev Panam Salud Publica; 2015 Jun; 37(6):430-4. PubMed ID: 26245179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
